JP2025024102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025024102A5 JP2025024102A5 JP2024199397A JP2024199397A JP2025024102A5 JP 2025024102 A5 JP2025024102 A5 JP 2025024102A5 JP 2024199397 A JP2024199397 A JP 2024199397A JP 2024199397 A JP2024199397 A JP 2024199397A JP 2025024102 A5 JP2025024102 A5 JP 2025024102A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- psychosis
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776247P | 2018-12-06 | 2018-12-06 | |
| US62/776,247 | 2018-12-06 | ||
| US201962829796P | 2019-04-05 | 2019-04-05 | |
| US62/829,796 | 2019-04-05 | ||
| PCT/US2019/064646 WO2020118032A1 (en) | 2018-12-06 | 2019-12-05 | Methods of treating neurological and psychiatric disorders |
| JP2021531942A JP2022511509A (ja) | 2018-12-06 | 2019-12-05 | 神経障害および神経障害の処置方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531942A Division JP2022511509A (ja) | 2018-12-06 | 2019-12-05 | 神経障害および神経障害の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025024102A JP2025024102A (ja) | 2025-02-19 |
| JP2025024102A5 true JP2025024102A5 (enExample) | 2025-06-10 |
Family
ID=69024675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531942A Pending JP2022511509A (ja) | 2018-12-06 | 2019-12-05 | 神経障害および神経障害の処置方法 |
| JP2024199397A Pending JP2025024102A (ja) | 2018-12-06 | 2024-11-15 | 神経障害および神経障害の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531942A Pending JP2022511509A (ja) | 2018-12-06 | 2019-12-05 | 神経障害および神経障害の処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200179336A1 (enExample) |
| EP (1) | EP3890726A1 (enExample) |
| JP (2) | JP2022511509A (enExample) |
| KR (1) | KR20210100667A (enExample) |
| CN (2) | CN118576586A (enExample) |
| AU (2) | AU2019394956B2 (enExample) |
| CA (1) | CA3122261A1 (enExample) |
| MX (1) | MX2021006553A (enExample) |
| WO (1) | WO2020118032A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104193761B (zh) | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| EP3582815A1 (en) | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| SG11202007823PA (en) | 2018-02-16 | 2020-09-29 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| KR20230003503A (ko) | 2020-04-14 | 2023-01-06 | 선오비온 파마슈티컬스 인코포레이티드 | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 |
| US20220165391A1 (en) * | 2020-11-25 | 2022-05-26 | Kyndryl, Inc. | Multi-stage treatment recommendations |
| KR20240110935A (ko) * | 2021-09-23 | 2024-07-16 | 스미토모 파마 아메리카, 인크. | 대사 장애를 치료하는 방법 |
| CA3260160A1 (en) | 2022-08-30 | 2024-03-07 | Sumitomo Pharma America, Inc. | ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER |
| AU2023358704A1 (en) | 2022-10-13 | 2025-05-29 | Sumitomo Pharma America, Inc. | Methods of reducing physical dependence to neuropsychiatric treatments |
| WO2024092070A1 (en) * | 2022-10-28 | 2024-05-02 | Sumitomo Pharma America, Inc. | Ulotaront for treating anxiety and associated conditions |
| CN120187422A (zh) | 2022-11-15 | 2025-06-20 | 住友制药美国公司 | 使用ulotaront转换神经精神病学药物的方法 |
| CN115754079B (zh) * | 2022-11-28 | 2025-04-04 | 合肥和合医疗科技有限公司 | 一种同时检测7种精神药物及其代谢产物含量的方法 |
| CN117594119B (zh) * | 2024-01-17 | 2024-05-10 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
| WO2025252814A1 (en) | 2024-06-04 | 2025-12-11 | Duc Duy Vo | Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof |
| WO2026015878A1 (en) * | 2024-07-12 | 2026-01-15 | Mindx Therapeutics, Inc. | A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104193761B (zh) | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| EP3582815A1 (en) * | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| SG11202007823PA (en) | 2018-02-16 | 2020-09-29 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| WO2019161236A1 (en) * | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Methods of treating social function disorders |
-
2019
- 2019-12-05 CN CN202410509785.9A patent/CN118576586A/zh active Pending
- 2019-12-05 KR KR1020217020606A patent/KR20210100667A/ko not_active Ceased
- 2019-12-05 JP JP2021531942A patent/JP2022511509A/ja active Pending
- 2019-12-05 CN CN201980087996.5A patent/CN113271936A/zh active Pending
- 2019-12-05 MX MX2021006553A patent/MX2021006553A/es unknown
- 2019-12-05 CA CA3122261A patent/CA3122261A1/en active Pending
- 2019-12-05 WO PCT/US2019/064646 patent/WO2020118032A1/en not_active Ceased
- 2019-12-05 AU AU2019394956A patent/AU2019394956B2/en active Active
- 2019-12-05 US US16/704,202 patent/US20200179336A1/en not_active Abandoned
- 2019-12-05 EP EP19828449.9A patent/EP3890726A1/en active Pending
-
2024
- 2024-02-01 US US18/429,524 patent/US20240350453A1/en not_active Abandoned
- 2024-11-15 JP JP2024199397A patent/JP2025024102A/ja active Pending
-
2025
- 2025-01-08 US US19/013,028 patent/US20250312308A1/en active Pending
- 2025-08-06 AU AU2025213591A patent/AU2025213591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511509A5 (enExample) | ||
| Hong et al. | Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease | |
| JP2022191257A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP2024540183A5 (enExample) | ||
| JP2017511339A5 (enExample) | ||
| JP2020505408A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| JP2017516868A5 (enExample) | ||
| JP2014514271A5 (enExample) | ||
| Cutler et al. | Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial | |
| JP2013500977A5 (enExample) | ||
| JP2018531975A5 (enExample) | ||
| IL274045B2 (en) | Prodrugs of dantrolene and methods of using them | |
| JP2020520963A5 (enExample) | ||
| JP2024536126A5 (enExample) | ||
| JP2022524325A5 (enExample) | ||
| Donohue et al. | Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: evaluation in phase 3 clinical trials | |
| JP2012502105A5 (enExample) | ||
| JP2019507785A5 (enExample) | ||
| Xiao et al. | Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study | |
| JP2021527692A5 (enExample) | ||
| JP2020535139A (ja) | シポニモドの投与レジメン | |
| JP2023551943A5 (enExample) | ||
| JP2024511057A5 (enExample) |